Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Known for its biocompatibility, viscoelasticity, and exceptional water-retaining capabilities, HA plays a pivotal role across numerous therapeutic areas. Notably, ophthalmology was the first field to harness the power of HA, setting the stage for decades of innovation in ocular treatments.
Found naturally in the eye and connective tissues, HA contributes to lubrication, maintaining tissue hydration, and cellular repair — features that are particularly beneficial in the delicate environment of ocular structures. Since its first FDA approval in 1979 with Healon, HA has become foundational in a wide array of ophthalmic procedures and therapies.
One of HA’s earliest and most established uses is in cataract surgery. HA-based viscoelastics are used to maintain the anterior chamber, protect the corneal endothelium, and support intraocular lens (IOL) implantation. These formulations reduce mechanical trauma and ensure a smoother surgical process. 2
In corneal transplants, HA helps preserve donor corneas by maintaining hydration and structural integrity. This contributes to better tissue viability and postoperative healing, supporting the graft’s integration into the host eye. 2
During procedures such as goniotomy or trabeculectomy, HA maintains space within the eye, helping to prevent tissue collapse and aid surgical precision. It also contributes to improved postoperative recovery by reducing inflammation and supporting wound healing. 2
HA-based eye drops are a frontline treatment for dry eye syndrome. By enhancing tear film stability and hydrating the ocular surface, HA alleviates symptoms such as irritation, burning, and visual fatigue. Its ability to retain moisture makes it particularly effective for long-term management. 3, 4, 5
As research advances, HA continues to be at the center of innovative solutions in eye care.
HA is being studied as a carrier for intravitreal injections, particularly for retinal conditions like age-related macular degeneration (AMD) and diabetic retinopathy. By controlling drug release and extending therapeutic duration, HA-based systems could reduce injection frequency and improve patient outcomes. 6, 7, 8
HA-infused contact lenses and hydrogel formulations are being developed to accelerate healing after corneal injury or surgery. These materials deliver moisture and create a protective barrier that promotes epithelial regeneration. 9, 10
Cutting-edge delivery technologies are incorporating HA into mucoadhesive inserts, hydrogels, and nanoparticles. 7, 8 One example is a preclinical ophthalmic insert that transforms into a hydrogel pellet on the eye’s surface, delivering drugs steadily over several days—potentially transforming treatment adherence. 11
Postoperative scarring remains a risk in many ophthalmic procedures. HA’s anti-fibrotic potential is being explored to prevent excessive tissue formation, particularly after glaucoma surgeries. Reducing scarring could preserve surgical success and long-term vision outcomes. 3, 10, 12
Cutting-edge research is now focusing on customizing HA molecules to enhance therapeutic properties. Scientists are also investigating its integration with stem cell therapies for retinal regeneration, aiming to create supportive scaffolds that promote cellular differentiation and repair in degenerative eye diseases.
Additionally, HA is being explored for use as an artificial vitreous substitute—a potential game-changer for patients undergoing vitrectomy for retinal conditions.
From its foundational role in cataract surgery to its promise in next-generation regenerative medicine, hyaluronic acid continues to redefine what’s possible in ophthalmology. Its unique combination of hydration, lubrication, and biocompatibility makes it an essential molecule in both established procedures and pioneering research.
Hyaluronic Acid (HA) has already secured its place as a gold-standard biopolymer across medical and aesthetic fields. Celebrated for its unique viscoelasticity, hydration capacity, and biocompatibility, HA has long been used in ophthalmic surgery, joint viscosupplementation, wound healing, and dermal fillers. But today, HA is undergoing a radical transformation. It’s becoming an active, programmable platform—a cornerstone of the next generation of drug delivery and regenerative medicine.
Earlier this year, during the IMCAS World Congress, we interviewed three experts in the field of aesthetic medicine and are thrilled to share these exclusive interviews !
Polynucleotides (PDRN /PN) are emerging as a key biopolymer in regenerative medicine, offering innovative solutions for tissue repair, wound healing, and aesthetic medicine. With their unique mechanism of action and promising therapeutic applications, polynucleotides are revolutionizing the field of biopolymer-based treatments. In this article, we will explore what polynucleotides are, how they work, their medical applications, and their sustainable sourcing from wild salmon.